Minneapolis-based Fasikl has obtained FDA 510(ok) clearance for its Felix NeuroAI Wristband for adults with important tremor.
The wearable combines AI and neurotechnology to modulate the nervous system to assist alleviate practical limitations attributable to tremors.
The corporate’s AI repeatedly adjusts stimulation parameters to supply remedy that calms tremors and helps restore motor management.
Fasikl touts that Felix offers reduction for each arms, even when the wearer solely has the wristband on one arm, and will help sufferers with gentle, reasonable and extreme tremors.
“We’re getting into an thrilling new chapter, not only for Fasikl, however for the thousands and thousands of individuals residing with important tremor who’ve lengthy been underserved. Our subsequent step is a targeted industrial launch of the Felix NeuroAI Wristband, starting in choose U.S. areas in 2025, with a nationwide rollout deliberate for 2026,” Zhi Yang, CEO of Fasikl, advised MobiHealthNews in an e mail.
“With Felix, we’re pioneering a brand new class of non-invasive, AI-powered remedy that provides actual, every day reduction with out the negative effects and dangers of medicine or surgical procedure. That is only the start of what AI can do in neuromedicine, and we’re excited to carry this remedy to the individuals who want it most.”
THE LARGER TREND
Final 12 months, Fasikl closed a $18.3 million Sequence A+ funding spherical co-led by iSeed and Tailwinds Ventures.
In 2023, Fasikl obtained FDA breakthrough machine designation for 2 of its choices: MindForce, a nerve-computer interface system designed to permit amputees to manage robotic limbs utilizing their thoughts, and Epione, an providing supposed to alleviate post-amputation ache.
That very same 12 months, the corporate closed a $10 million Sequence A fairness funding spherical, and in 2021, it secured $5 million in pre-Sequence A fairness funding.
